TL;DR
- The informed consent model allows trans adults to access HRT after a thorough discussion of risks, benefits, and alternatives — without requiring formal psychiatric sign-off or mandatory mental health referral as a prerequisite
- It is not a shortcut. It is the same standard of patient autonomy applied to almost every other medical decision in adult medicine
- WPATH SOC-8 has moved away from some of the mental-health gatekeeping requirements in earlier versions, and a growing body of clinical literature describes informed consent as a recognised model operating alongside it
- A study of one Australian informed consent clinic found high patient satisfaction; the direct comparative outcomes research between models that would settle the broader question has not yet been done
- The alternative — gatekeeping — has no demonstrated evidence base for improving outcomes, and waiting itself has documented evidence of causing harm through delay
The informed consent model is not a new idea. It reflects the principles of patient autonomy that underpin much of adult medicine.
When an adult decides to take medication for blood pressure, for depression, for contraception, for virtually any condition where the risks and benefits are known — a clinician explains those risks and benefits, the patient demonstrates understanding, and treatment begins. There is no committee. There is no waiting period. There is no requirement that a psychiatrist certify the decision is genuine before a prescription is written.
Historically, access to HRT has often involved additional assessments and mental health referrals that differ substantially from the approach used for many routine medical decisions in competent adults.
The informed consent model restores a model of care more closely aligned with the principles of autonomy used throughout much of adult medicine.
What it actually involves
Informed consent for HRT is not a rubber stamp. A thorough informed consent consultation covers: the effects of hormone therapy and the expected timeline; the risks, including cardiovascular, thrombotic, and fertility implications; what is reversible and what is not; alternatives to medical transition; what monitoring will be required and why; and the patient’s understanding of all of the above.
In informed consent pathways, the focus is generally not on validating a patient’s identity but on ensuring that the patient understands the treatment, its risks, and its alternatives.
Fertility preservation is discussed as part of informed consent — both WPATH and the Endocrine Society recommend that all trans people be counselled about reproductive implications before beginning HRT. General health, current medications, and support structures are also assessed — not as gatekeeping criteria, but as clinically relevant information for safe prescribing.
What the evidence shows
A retrospective study of an informed consent clinic in Melbourne, Australia found high levels of satisfaction among the informed consent patients surveyed. A separate Australian study comparing patients across a WPATH-model clinic and an informed consent clinic found that WPATH-model patients had more psychiatric diagnoses and required more assessment sessions before starting hormone therapy than informed consent patients — but that study did not collect data on long-term health outcomes or regret in either group, and its own authors identified longitudinal outcomes research comparing the two models as a needed next step rather than something already established.
This means the honest state of the evidence is this: there is no published study demonstrating that strict psychiatric assessment produces better long-term outcomes than informed consent pathways, but there is also not yet a direct, well-powered comparative outcomes study showing the two models are equivalent. The absence of evidence for gatekeeping’s benefit is not the same as proof that informed consent is just as safe — though it is a meaningful gap, given how long psychiatric gatekeeping has been the default and how rarely its benefit has been tested directly.
WPATH SOC-8 reduced or removed some of the mental-health letter requirements present in earlier versions of the Standards of Care, reflecting a broader shift in the field’s thinking about the role of psychiatric gatekeeping. A growing body of independent clinical and ethics literature describes informed consent as a recognised model of care operating alongside, and sometimes in place of, the traditional WPATH-referral pathway, rather than as a departure from responsible practice.
Why it matters
In systems where access depends on multiple referrals and assessments, delays may accumulate before treatment begins, for care that, in many cases, could potentially begin earlier. Prolonged delays are associated with adverse mental health outcomes, including increased rates of depression, anxiety, and suicidality during the period of untreated gender dysphoria.
The informed consent model does not remove clinical judgment. It reframes where that judgment belongs — with the clinician providing safe, monitored care, not with a gatekeeper deciding whether someone has earned the right to their own healthcare.
Patient autonomy is not a concession to be made when gatekeeping fails. It is the baseline.
⚠️ Note: The informed consent model applies to adults. Approaches to care for transgender minors involve additional considerations and are distinct from adult informed consent pathways. This post addresses adult trans healthcare only.
Sources
- Spanos C, Grace JA, Leemaqz SY, et al. The Informed Consent Model of Care for Accessing Gender-Affirming Hormone Therapy Is Associated With High Patient Satisfaction. J Sex Med. 2021;18(1):201–208.
- Solanki P, Colon-Cabrera D, Barton C, et al. Gender-Affirming Hormone Therapy for the Trans, Gender Diverse, and Nonbinary Community: Coordinating World Professional Association for Transgender Health and Informed Consent Models of Care. Transgender Health. 2023;8(2):137–148.
- Coleman E, Radix AE, Bouman WP, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. International Journal of Transgender Health. 2022;23(S1):S1–S259.
- Cavanaugh T, Hopwood R, Lambert C. Informed consent in the medical care of transgender and gender-nonconforming patients. AMA J Ethics. 2016;18(11):1147–1155.
- Ashley F, St Amand CM, Rider GN. The continuum of informed consent models in transgender health. Fam Pract. 2021;38(4):543–544.
